Acquisition by Sean Power of 75000 shares of TG Therapeutics subject to Rule 16b-3
| TGTX Stock | USD 34.01 0.39 1.13% |
Slightly above 54% of TG Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding TG Therapeutics suggests that many traders are impartial. TG Therapeutics' investing sentiment can be driven by a variety of factors including economic data, TG Therapeutics' earnings reports, geopolitical events, and overall market trends.
TGTX |
Filed transaction by TG Therapeutics Officer Cfo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
TG Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the TG Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
TG Therapeutics Fundamental Analysis
We analyze TG Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
TG Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
TG Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TG Therapeutics stock to make a market-neutral strategy. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics with similar companies.
Peers
TG Therapeutics Related Equities
| XFOR | X4 Pharmaceuticals | 10.23 | ||||
| AKRO | Akero Therapeutics | 6.06 | ||||
| VKTX | Viking Therapeutics | 0.43 | ||||
| HEPA | Hepion Pharmaceuticals | 1.26 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.69 | ||||
| PDSB | PDS Biotechnology | 2.06 | ||||
| TERN | Terns Pharmaceuticals | 2.72 | ||||
| EXEL | Exelixis | 4.32 | ||||
| BTAI | BioXcel Therapeutics | 4.63 |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.